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Abstract
Amplification of 8p12-p11 is relatively common in breast cancer and several
genes within the region have been suggested to affect breast tumor progression.
The aim of the study was to map the amplified 8p12-p11 region in a large set
of breast tumors in an effort to identify the genetic driver and to explore its
impact on tumor progression and prognosis. Copy number alterations (CNAs)
were mapped in 359 tumors, and gene expression data from 577 tumors (359
tumors included) were correlated with CNA, clinical–pathological factors, and
protein expression (39 tumors). 8p12-p11 was amplified in 11.4% of tumors.
The smallest region of amplification harbored one full-length gene, ZNF703.
ZNF703 mRNA expression was significantly higher in estrogen receptor
(ER)-positive than ER-negative tumors (P = 2 9 1016), a reflection of high
expression in luminal tumors. Forty-eight percent of tumors with ZNF703
amplification were luminal B tumors in which the best correlation between
DNA copy number and mRNA was seen (P = 1.2 9 107) as well as correla-
tion between mRNA and protein expression (P = 0.02). High ZNF703 mRNA
correlated with poor survival in patients with ER-positive luminal B tumors
(log rank P = 0.04). Furthermore, high ZNF703 mRNA expression correlated
with poor outcome in patients with ZNF703 copy number neutral, ER-positive,
luminal B tumors (log rank P = 0.004). The results support ZNF703 as the driver
gene of the 8p12 amplification and suggest that independent of amplification,
high expression of the gene affects prognosis in luminal B tumors.
Introduction
Amplifications are common in breast cancer. Some of the
genes within the amplicons are oncogenes that drive the
amplification while others are passengers. Amplifications at
8p12-p11 occur in 10–15% of breast tumors [1–6] and have
been associated with poor prognosis and shorter survival
[3, 7–9]. The complex pattern of the 8p12-p11 amplifica-
tion undoubtedly has delayed the identification of a genetic
driver. Four amplicons, A1–A4, have been mapped consis-
tently in the 8p12-p11 region where the telomeric amplicon
A1 is most often amplified [3, 9–13]. Five genes – ZNF703,
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ERLIN2, PROSC, BRF2, and RAB11FIP1 – residing within
A1 were indicated as potential drivers of the amplicon
based on positive correlation between DNA amplification
and gene expression [3, 10–13]. ERLIN2 [14] was shown to
have transforming properties in breast cancer cell lines as
well as RAB11FIP1 [15], which also had tumorigenic prop-
erties in mouse xenograft models. Two studies, in which a
large number of breast tumors were used, demonstrated
that ZNF703 meets the criteria as the genetic driver of the
A1 amplicon, emerging as a gene with an oncogenic role in
luminal B type breast cancer [16, 17]. This was recently
confirmed in a large study of the genome and transcrip-
tome in 2000 breast tumors [18]. Alteration of ZNF703
expression has been shown to affect cellular gene expression
allowing cells to evade replication constraints and steer
them toward self-renewal rather than differentiation [16,
17]. Its role in breast cancer progression, or metastasis, was
demonstrated in a mouse model of breast cancer where
enhanced ZNF703 expression repressed E-cadherin expres-
sion and increased lung metastases [19]. Loss of E-cadherin,
which promotes cellular adhesion in normal breast
epithelial cells, increases the proliferative and invasive
potential of breast cancer cells, which can promote epithe-
lial mesenchymal transition and metastasis [20]. These
functions suggest that ZNF703 plays an important role in
breast cancer formation and progression.
The luminal B subtype of breast tumors along with the
luminal A subtype are two of five molecular subtypes that
have been defined by gene expression analysis [21, 22]. The
different classes of molecular subtypes predict patient prog-
nosis [22–24] and aid in prediction of response to neo-
adjuvant treatment in node-negative patients [25]. The
luminal subtypes constitute the majority of tumors that
express the estrogen receptor (ER), which is expressed in
two thirds of all breast tumors. As patients with luminal B
tumors have a higher risk of relapse than patients with
tumors of the luminal A subtype [22–24], there has been
an effort to distinguish between them. Tumors of the lumi-
nal B subtype are commonly of higher grade compared
with luminal A tumors [26], and proliferative genes such as
Ki67 [27] are more highly expressed [22, 24] in luminal B
tumors. The luminal tumors can also be distinguished
based on their genomic subtypes, where luminal A tumors
have fewer copy number alterations (CNAs) – amplifications
and losses – than tumors of the luminal B subtype [28].
Our mapping of the 8p12-p11 region in 359 Nordic
breast tumors resulted in the identification of ZNF703 as
the only full-length gene within the minimal region of
amplification. It was found to be expressed mainly in ER-
positive tumors, highest and most frequent in the ER-
positive luminal B subtype. In addition, high ZNF703
mRNA levels in luminal B tumors resulted in poor prog-
nosis even in the absence of gene amplification.
Materials and Methods
Patients and breast tumor samples
The breast tumor samples were obtained from the Depart-
ment of Pathology, Landspitali-University Hospital in Rey-
kjavik, Iceland, the Department of Oncology, Skane
University Hospital, Lund, Sweden, and from the Helsinki
University Central Hospital, Finland. As explained in Jons-
son et al. [29], approval was obtained from ethical commit-
tees for the Icelandic, Swedish, and Finnish tumor
specimens in the respective countries: The Icelandic
Data Protection Committee (2001/523 and 2002/463),
the National Bioethics Committee of Iceland (99/051 and
99/051_FS1), the regional Ethical Committee in Lund (reg.
no. LU240-01 and 2009/658), and the Helsinki University
Central Hospital Ethical Committee (207/E9/07).
Gene expression
Array-GEX for ZNF703 was retrieved for 577 samples
from the Gene Expression Omnibus (GEO) dataset
GSE25307 [29]. In order to verify the results, a quanti-
tative real-time polymerase chain reaction (qRT-PCR)
was performed on all available tumor samples, which
was a subset (n = 137) of the tumors from the Icelandic
patients (n = 161). RNA was extracted from fresh frozen
tumors using Trizol, purified by RNeasy Midi purifica-
tion kit (Qiagen, Hilden, Germany), and 2 lg was
reverse transcribed with random hexamer primers using
the RevertAid Minus First strand cDNA synthesis kit
(Thermo Fisher Scientific, Vilnius, Lithuania). One nano-
gram of cDNA was used as template. Taqman Gene Expres-
sion Assay Hs00228155_m1 was used for ZNF703 and the
TATA-binding protein (TBP, 4326322E Applied Bio-
systems, Nærum, Denmark) was a reference gene. Expression
level of the target genes relative to the reference gene was
quantified as follows: mRNA expression of target
gene = 2(mean Ct target  mean Ct reference). A correlation was
observed between the ZNF703 mRNA values obtained by
the two methods (r = 0.75, P = 2 9 1016).
BAC array-CGH analysis
Bacterial artificial chromosome (BAC) array-comparative
genomics hybridization (CGH) data were obtained for
359 tumors from GEO dataset GSE22133 [28], inclusive
in the set of 577 samples from the GSE25307 dataset. The
BAC clones were mapped by the BACPAC consortium to
hg17 in 2004. To analyze CNAs within 8p12-p11, break-
point analysis was performed using circular binary seg-
mentation (CBS) with a = 0.001 [30]. The minimum
number of BACs per segment was 4. Gaps between
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segments were closed by extending the adjacent segments
into the center of the gap. The threshold for loss was set
to segmented log2 ratio less than 0.32, gain was set to
segmented log2 ratio 0.5, and amplification was set to seg-
mented log2 ratio 0.85. Loss, gain, and amplification were
observed in 34, 29, and 41 tumors, respectively. The 41
tumors showing amplification were used to map the small-
est region of overlap (SRO) that was most often amplified.
Clinical parameters and pathology
Clinical, pathological, and molecular characteristics were
retrieved from the GSE25307 dataset [29] and can be seen
in Table S1. The histopathology of the tumors was cate-
gorized according to the WHO histological classification
and the histological grade was determined by the modi-
fied Bloom–Richardson system. The ER and progesterone
(PR) status was determined as being either positive
(staining 1+ to 3+) or negative (no staining).
Tumor protein extraction, Western blotting,
and protein quantification
Protein expression was analyzed in 39 Icelandic breast
tumors. The power to detect a correlation using 39
tumors, assuming an effect size of 0.5 and a = 0.05, was
0.9. Twelve tumors were of the luminal A subtype, 10
were luminal B, 4 were normal like, and 6 were basal.
The subtype was not available (NA) for six tumors and
one tumor originated in another organ and was not rele-
vant. Protein was extracted from approximately 100 lg
of breast tumor tissue that had been fresh frozen in
liquid N2; 5 lg of each tumor sample was subjected to
SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel
electrophoresis) and Western blotting according to stan-
dard protocols using 0.25 lg/mL of ZNF703 antibody
(Abcam ab40861) followed by 0.06 lg/mL of GAPDH
antibody (RDI) that was used as a loading control prior
to ECL development and exposure to film. The antibody
detected the full-length 58.2 kDa isoform that has been
approved by the CCDS database (http://www.ncbi.nlm.
nih.gov/CCDS/CcdsBrowse.cgi). The films were scanned
and the protein was quantified in Photoshop CS2
(Adobe). The absolute intensity of a protein band was
obtained by subtracting the background from the value
of the protein band and multiplying by the pixel value.
The absolute value of each protein band was divided by
the respective value of GAPDH, which allowed compari-
son of the relative protein expression within each gel.
Cell lysate from the breast cancer cell line SUM52, which
was cultured under the condition recommended by Ast-
erand, was included on all gels to allow comparison
between gels.
Statistical analysis
Statistical analyses, including the survival analyses using
the Survival package, were performed in R [31] (http://
www.r-project.org) version 2.11.1. Correlation of ZNF703
mRNA level with clinical, molecular, or tumor character-
istics was performed for 577 samples unless otherwise
specified. Three-hundred and fifty-nine tumors, a subset
of the 577 samples, were used for correlation analysis of
ZNF703 mRNA levels with ZNF703 copy number due to
the limiting number of tumors with array-CGH data. The
ZNF703 mRNA levels were analyzed according to ZNF703
copy number status using nonparametric analysis. The
Pearson correlation coefficient was calculated to analyze
correlation between protein quantity and mRNA expres-
sion. Correlation of ZNF703 mRNA levels with molecular
subtypes, histopathology, and clinical parameters was per-
formed with parametric tests, Student’s t-test, or analysis
of variance (ANOVA).
To examine the effect of ZNF703 mRNA expression on
survival in patients carrying ER-positive luminal (com-
bined luminal A and B) or luminal B tumors, the tumors
were divided into high expressing tumors, whose relative
expression of ZNF703 mRNA was  the mean and
tumors expressing low ZNF703 mRNA, that is, below the
mean. The survival curves were compared using Kaplan–
Meier estimates and the log rank test.
Results
ZNF703 is the only gene within the smallest
region of overlap at 8p12
CNAs were mapped by array-CGH hybridizations of the ge-
nomes of 359 breast tumors from Nordic patients. There
was amplification (log2 ratio >0.85) within the 8p12-p11
locus in 41 (11.4%) tumors. Amplification of the telomeric
8p12 region was most frequently observed, 31 (75%) of the
41 tumors. These 31 tumors were used to define the SRO
that was amplified. The telomeric boundary of the SRO was
upstream of ZNF703 (Fig. 1A) in a region where no known
genes reside (hg17 [32]). Two luminal B tumors,
TAX577473 and TAX577192, define the centromeric
boundary that was demarcated by a break between amplifi-
cation (log2 ratio 1) and gain (log2 ratio 0.6). The boundary
falls within intron 3 of the ERLIN2 gene, leaving inside the
SRO, ZNF703, and a noncoding exon 1 as well as exons 2
and 3 of the ERLIN2 gene that code for 69 amino acids. The
SRO thus encompassed a genetic region whose only full-
length gene was ZNF703. In tumor samples TAX577473
and TAX577192 there was high expression from ZNF703
but not from ERLIN2. Hence, ERLIN2 was excluded as the
genetic driver of the telomeric 8p12 amplicon.
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Figure 1. ZNF703, the only full-length gene within the smallest region of overlap (SRO), exhibits the best correlation between DNA and mRNA
levels in tumors of the luminal B subtype. (A) The SRO at the amplified 8p12 region included ZNF703. The CNAs between 37.1 and 38.2 kb from
selected tumors are shown. The IGV heatmap (http://www.broadinstitute.org/igv [36, 37]) shows the alignment of the copy number data from
the indicated tumors, which was used to define the telomeric and centromeric border of the SRO. The telomeric and centromeric boundaries of
the SRO within 8p12-p11 mapped to genomic positions 37368027 and 37717593, respectively (hg 17). The black dotted lines and bracket
demarcate the SRO. The scale on the right depicts the log2 transformed values for the BACs. (B) Tumors were placed into the categories loss,
neutral, gain, and amplification (amp) depending on the copy number values. The number of tumors in each category is indicated below the plot.
A Kruskal–Wallis analysis was performed to analyze the correlation between mRNA expression and DNA copy number for the whole group and in
the individual subtypes: all tumors, P = 8.7 9 1016; luminal B subtype, P = 1.2 9 107; luminal A, P = 1.7 9 103; normal like, P = 0.02;
ERBB2, P = 0.6; and basal, P = 0.3.
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ZNF703 protein and mRNA expression
correlate in tumors of the luminal B subtype
The 359 Nordic tumors used for analysis of correlation
between ZNF703 mRNA and copy number represented the
molecular subtypes – 79 basal, 34 ERBB2, 95 luminal A,
70 luminal B, 34 normal like, and 47 unclassified. Amplifi-
cation of ZNF703 was observed in 4 (5.1%) of 79 basal
tumors, none of 34 (0%) ERBB2 tumors, 6 (6.3%) of 95
luminal A tumors, 15 (21.4%) of 70 luminal B tumors,
2 (5.9%) of 34 normal-like tumors, and 4 (8.5%) of 47
unclassified tumors. Thus, the dominant subtype with
amplification of ZNF703 was the luminal B subtype (48%
of tumors), with the remaining amplified tumors of
subtypes luminal A (19%), basal (13%), normal like (7%),
and unclassified (13%) (Fig. S1). The ZNF703 mRNA levels
were highest in luminal B tumors (Fig. S2). Categorization
of tumors according to mRNA expression into high expres-
sion (>1 SD, n = 39) and normal expression (1 SD,
n = 320) revealed that 0% of basal (0/79), 0% of ERBB2
(0/34), 9.5% of luminal A (9/95), 31.4% of luminal B
(22/70), 11.8% of normal like (4/34), and 8.5% of unclassi-
fied (4/47) tumors expressed high ZNF703 mRNA levels.
Therefore, 56.4% or 22 of the 39 tumors that expressed
high levels of ZNF703 mRNA were of the luminal B
subtype. Correlation of ZNF703 mRNA with ZNF703 copy
number categorized according to amplification, gain, loss,
or neutral status revealed the strongest correlation in the
luminal B (P = 1.2 9 107) subtype followed by the lumi-
nal A (1.7 9 103) and normal-like (P = 0.02) subtypes,
but no correlation was observed in the ERBB2 or basal
subtypes (Fig. 1B). From these analyses it became clear that
some of the tumors that were copy neutral for ZNF703 also
expressed high levels of ZNF703 mRNA.
To determine whether the correlation between ZNF703
copy number and mRNA level reflected protein level, pro-
tein expression was analyzed by Western blotting in 39
tumors, including 12 luminal A tumors, 10 luminal B
tumors, and 4 normal-like tumors (Fig. 2). Only the large
isoform (58.2 kDa) of ZNF703 was observed. A significant
positive correlation between ZNF703 mRNA and protein
levels was observed in luminal B tumors (r = 0.75,
P = 0.02; Fig. 2C) but not in tumors of the luminal A sub-
type (data not shown). Expression of ZNF703 protein was
significantly higher in luminal B tumors than in luminal A
tumors (P = 0.008). ZNF703 protein expression was not
detected in the normal-like tumors. Although the number
of tumors is small the results suggest a correlation between
DNA amplification and gene expression of ZNF703 at the
protein level in luminal B tumors.
A B C
Figure 2. Protein expression from ZNF703 correlated positively with mRNA expression in luminal B tumors. (A) ZNF703 protein expression was
analyzed by Western blotting in 39 breast tumors. The Western blots were probed with antiserum against ZNF703 and GAPDH as a loading
control. S stands for the breast cancer cell line SUM52 and the tumor samples are numbered from 1 to 39. Molecular weight (kDa) markers are
shown on the left. The molecular weight of the full-length ZNF703 protein is 58.2 kDa. **Nonspecific binding. Ig denotes the detection of
immunoglobulins by the secondary goat antiserum against the primary ZNF703 antiserum. (B) The table shows the sample identifiers, subtype,
and the relative protein level of ZNF703. The tumors labeled with * most closely matched the indicated subtype (see Materials and Methods). The
quantification of ZNF703 with respect to GAPDH was as described in methods. ND denotes that no ZNF703 expression was detected, NP means
that no protein was observed in the lane, and NR is not relevant (not breast tumor). No protein expression (ND) was not due to no or little mRNA
expression in the tumor. (C) Correlation analysis between log2 transformed ZNF703 protein and mRNA levels in luminal B tumors. The Pearson
correlation coefficient was r = 0.75, P = 0.02.
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High ZNF703 mRNA levels correlate with
shorter survival
The correlation of ZNF703 mRNA with clinical and patho-
logical characteristics in 577 Nordic tumors [29]
confirmed highest expression in tumors of the luminal B
subtype and the lowest in the basal subtype
(P = 2 9 1016; Fig. S2). Also, ZNF703 mRNA expres-
sion was higher in hormone receptor–positive tumors
(P = 2 9 1016). Luminal A and luminal B tumors con-
stitute the majority of the ER-positive tumors. They were
also the subtypes in which DNA copy number and mRNA
levels were most significantly correlated. We therefore
analyzed the effect of ZNF703 mRNA expression on prog-
nosis in these subtypes by testing for a potential correla-
tion of ZNF703 mRNA expression with clinical and
pathological parameters.
Correlation between histoclinical parameters and
ZNF703 mRNA levels in ER-positive luminal tumors
revealed higher ZNF703 mRNA levels in PR-negative
tumors (P = 0.008), a gradual increase in mRNA accord-
ing to histological grade (P = 0.04), and an increased
number of deaths was observed in patients with tumors
containing high levels of ZNF703 mRNA (P = 0.002,
Table 1). No difference was observed in ZNF703 mRNA
according to the histological origin of the tumor or age at
diagnosis. The significant difference in ZNF703 mRNA
according to BRCA mutation status was due to higher
expression in BRCA2-mutated tumors as compared with
sporadic tumors, which is explained by the high ratio of
BRCA2-mutated ER-positive luminal tumors belonging to
the luminal B subtype (80%). There was a trend toward
shorter overall survival (OS) in patients with ER-positive
luminal tumors, expressing high (above the mean)
ZNF703 mRNA levels (log rank P = 0.06, Fig. 3A). Half
of the ER-positive luminal B tumors expressed high levels
of ZNF703 mRNA, but 31% of the ER-positive luminal A
tumors. Survival analysis of the luminal subtypes sepa-
rately showed that high ZNF703 mRNA led to shorter OS
in luminal B tumors (log rank P = 0.04, Fig. 3B), whereas
a significant difference was not observed in luminal A
tumors (data not shown). The hazard ratio (HR) for
ZNF703 mRNA in luminal B tumors was 1.90 (95% con-
fidence interval [CI] 1.02, 3.54, P = 0.04), but an adjust-
ment for the histoclinical parameters could not be
performed due to low number of events [33]. A correla-
tion between ZNF703 expression levels and tumor charac-
teristics was not observed in the luminal B or luminal A
subtypes (Table S2). Some of the ZNF703 copy neutral
luminal A and B tumors express very high levels of
ZNF703 mRNA (Fig. 1B), which prompted the separate
analysis of these tumors. A significantly shorter OS was
observed in ER-positive luminal tumors (P = 0.008,
Fig. 4A) which was attributed to ER-positive luminal B
tumors (P = 0.004, Fig. 4B). High expression of ZNF703
was significantly associated with shorter survival in ER-
positive luminal tumors (HR 2.28, CI 1.30, 3.99,
P = 0.004), and after adjustment for PR expression (HR
2.17, CI 1.19, 3.93, P = 0.01; Table S3).
Discussion
Our results support previous studies that demonstrated
ZNF703 as an oncogene with a role in luminal B tumors
[16, 17]. Furthermore, we show that high ZNF703 mRNA
resulted in shorter OS in patients with ER-positive lumi-
nal B tumors, regardless of amplification. These results
suggest worse prognosis in patients with luminal B
tumors that express high level of ZNF703.
ZNF703 has been indicated as the genetic driver of the
amplification at 8p12 in luminal B tumors [16, 17]. In
one study the gene was identified when comparing geno-
Table 1. Correlation of ZNF703 mRNA levels in ER-positive luminal A
and luminal B tumors with clinical and pathological parameters.
ER pos luminal tumors n = 221
ZNF703 mRNA
level, mean (SD) P-value
Histopathology
IDC 150 1.98 (1.36) 0.26
ILC 16 1.88 (1.01)
Other 29 1.73 (1.14)
Unknown 26
Histologic grading
1 27 1.49 (0.71) 0.04
2 76 1.89 (1.35)
3 37 2.32 (1.64)
Unknown 81
Progesterone receptor
Negative 39 2.70 (1.94) 0.008
Positive 178 1.77 (1.11)
Unknown 4
Age
<50 97 1.90 (1.17) 0.50
50 119 1.97 (1.47)
Unknown 5
Mutation status
BRCA 1 2 2.64 (0.78) 0.0003
BRCA 2 25 2.55 (1.25)
BRCA X 78 2.10 (1.52)
Other 8 2.78 (2.43)
Sporadic 108 1.60 (0.99)
Death
No 136 1.75 (1.15) 0.002
Yes 84 2.26 (1.53)
Unknown 1
IDC, invasive ductal tumors; ILC, invasive lobular tumors. The mean
values of ZNF703 mRNA level are shown along with SD. The P-values
were calculated with a T-test (two variables) or an ANOVA (>2 vari-
ables) using the log2 transformed ZNF703 mRNA levels.
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mic alterations and gene expression between luminal A
and B tumors [17]. In another study, ZNF703 was the
only gene within the SRO [16]. Similarly in our study,
ZNF703 was the only full-length gene within the SRO in
two luminal B tumors that had a centromeric break point
within ERLIN2. The previous studies [16, 17] provided
support for ZNF703 being a class II oncogene in luminal
B breast tumors in keeping with a scheme that classifies
amplified cancer genes according to importance in cancer
development [34]. In accord with this scheme, our results
support ZNF703 as a class III oncogene [34]. Consistent
with the classical definition of an oncogene there was cor-
relation between gene amplification, mRNA, and protein
expression of ZNF703 in luminal B tumors. A positive
correlation between amplification and mRNA expression
of ZNF703 in breast tumors has not been observed con-
sistently. This is most likely due to heterogeneity of breast
tumors, tumor sample sets, and the fact that the strongest
correlation is in ER-positive [16] or in luminal B tumors
[17], as observed in this study, as well as lower or non-
existent correlation in other subtypes such as the ERBB2
and basal subtypes. Correlation with protein expression,
as measured by immunohistochemistry, has been reported
in one study in which protein expression was higher in
ER-positive tumors with amplification [16]. We measured
protein expression by Western blotting and observed the
ER positive luminal tumors
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full-length isoform of ZNF703. A positive correlation
between protein and mRNA levels was observed in lumi-
nal B tumors, which supports ZNF703 as an oncogene in
these tumors. However, the number of luminal B tumors
available to us was small and a higher number of luminal
B tumors are needed for confirmation. In a recent study
that identified genetic drivers based on the genomic and
transcriptomic landscape in breast tumors, ZNF703 was
identified as a genetic driver in some tumors of the lumi-
nal B, luminal A, and normal-like subtypes [18]. From
our data we can neither confirm nor preclude ZNF703 as
a genetic driver in normal-like and luminal A tumors.
Protein expression in luminal A tumors was lower than
in luminal B tumors and thus the correlation between
mRNA and protein may be weak and a larger sample size
would be necessary to observe a positive correlation. Pro-
tein expression was not detected in the normal-like
tumors preventing correlation analysis with mRNA.
High ZNF703 mRNA expression has been shown to
associate with shorter disease-free survival in a combined
analysis of luminal A and luminal B tumors [17]. We
confirm this observation by showing a trend in shorter
OS in patients with ER-positive luminal tumors express-
ing high ZNF703 mRNA. Additionally, we demonstrate
that high ZNF703 mRNA was associated with shorter OS
in patients with luminal B tumors (Fig. 3B), an observa-
tion not previously reported. The mean age at diagnosis
was 51 years (median age 48 years, range 26–88 years)
and thus the OS analyses were restricted to 15 years to
decrease the likelihood of deaths due to other causes.
Information regarding breast cancer–specific survival and
distant metastasis-free survival was not available for the
whole group of patients.
Patients with ZNF703 copy neutral, ER–positive, luminal
tumors expressing high ZNF703 mRNA had worse progno-
sis than those with tumors expressing low ZNF703 mRNA.
This finding was due to patients with ER-positive luminal
B tumors (Fig 4B). To our knowledge, this has not been
reported before but it appears that ZNF703 expression
above a certain threshold can impart a malignant character
to a cell. Thus, CNA may not be the only mechanism by
which the expression of ZNF703 is deregulated. At a cellu-
lar level, high expression from the ZNF703 gene has been
shown to activate the E2F1 transcription profile and down-
regulate the ER transcription profile which was proposed
to push the tumors toward a stem-like path (proliferation)
rather than a differentiation path [17]. An increase in
ZNF703 expression may also induce transcription of
growth factors or components of growth factor pathways
that enhance the proliferative or metastatic potential of
cells. Activation of growth factors in luminal B breast can-
cer has been suggested as a reason for resistance to therapy
and early relapse (reviewed in Tran and Bedard [35]).
Taken together, our results support ZNF703 as an
oncogene in breast cancer whose high expression pre-
disposes to poor clinical outcome in patients with luminal
B tumors. We suggest ZNF703 as a candidate for a marker
of worse prognosis, in particular for women with luminal
B breast cancer.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. Amplification of ZNF703 was most often
observed in tumors of the luminal B subtype. Amplification
of ZNF703 was observed in 31 (8.6%) of the 359 breast
tumors with available information on molecular subtypes.
Of these 13% (4/31) were of the basal subtype, 0% (0/31)
ERBB2, 19% (6/31) luminal A, 48% (15/31) luminal B, 7%
(2/31) normal like, and 13% (4/31) unclassified.
Figure S2. ZNF703 mRNA expression was observed in
tumors of the luminal B subtype. Comparison of
ZNF703 mRNA expression between the molecular sub-
types of breast cancer (basal [123], ERBB2 [59], luminal
A [149], luminal B [95], normal like [78], and unclassi-
fied [73]) showed that the expression is highest in the
luminal subtypes and lowest in the basal subtype. The
highest expression occurred in the luminal B tumors,
P = 2 9 1016.
Table S1. Clinical, pathological, and molecular character-
istics for the 577 tumors.
Table S2. Correlation of ZNF703 mRNA levels with clinical–
pathological parameters in ER-positive luminal B and luminal
A tumors.
Table S3. Hazard ratio (HR) and 95% confidence interval
(CI) for ZNF703 expression in copy neutral ER-positive
luminal tumors.
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